RESEARCH-USE BIOSIMILAR ANTIBODY
Emicizumab
Humanized modified IgG4 bispecific monoclonal antibody
Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab can be used for hemophilia A research.
TARGETFIXa
YBispecific monoclonal antibody
TARGETFX
CATALOG NUMBERSC-BS-001
MOLECULAR WEIGHTApprox. 145.6 kDa
PRODUCT FORMATBispecific monoclonal antibody
PRODUCT OVERVIEW
A research-use configuration for comparative antibody studies
Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab can be used for hemophilia A research.
Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis.